Trial Profile
An open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bimiralisib (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PIQUR Therapeutics
- 18 Oct 2018 Status changed from recruiting to completed.
- 21 Jul 2018 This trial has been completed in Spain.
- 20 Sep 2016 Status changed from not yet recruiting to recruiting.